Paul Koker

Suggest Changes
Learn More
BACKGROUND Olodaterol is a novel long-acting β2-agonist (LABA) with ≥24-h duration of action in preclinical and clinical studies. OBJECTIVE This Phase II, multicentre, randomised, double-blind,(More)
BACKGROUND Airway inflammation, mediated in part by LTB4, contributes to lung destruction in patients with cystic fibrosis (CF). LTB(4)-receptor inhibition may reduce airway inflammation. We report(More)
  • 1